Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Join MAP 2024, a global event on precision oncology and personalised medicine. Explore cancer biology, evolution, and molecular pathways to advance treatment and reshape cancer classification
A unique opportunity to explore the ESMO Guidelines in the context of real-world cases and have your questions answered during the live Q&A
How to mitigate the common biases and limitations in real world evidence studies? Secure your place today for the last webinar of this series to find out
Discover how the ESMO Guidelines can help you with the management of this serious complication of cancer and have your questions answered in the live Q&A with multidisciplinary expert commentary
The current state of the art in lung cancer therapy
Be a pioneer in breast cancer care – submit your abstract and present your breakthroughs at this international event
Shape the future of cancer drug development and be part of this unique forum gathering key actors in the field
It includes new recommendations in the first-line therapy with links to ESMO-MCBS scores and it is easy to refer to on desktop and mobile devices
Watch the recent ESMO Deep Dive: Breast Cancer webinar, available to all ESMO members to gain a deeper understanding of the clinical course of malignant disease of breast cancer
Share your cutting-edge research and innovative approaches with experts in Lugano, 20-22 March. Be part of this key oncology event!
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Updated data from two studies report significant improvements in recurrence-free survival and distant-metastasis free survival with pembrolizumab or nivolumab
Novel treatment approaches show encouraging early results in solid tumours, but ways to boost precision immunotherapy are needed
Efficacy and safety of telisotuzumab adizutecan was investigated in patients with EGFR wild type non-squamous disease
Together with an off-trial use and off-track access to oncology therapies, a consolidated trend is reported in clinical practice despite the uncertainties on efficacy and safety
Evidence from well-designed clinical trials is key to promote greater acceptance and access to palliative care
The combination therapy with the CDK 4/6 inhibitor improved overall response rate compared to standard treatment
Strategies to target MTAP deletion, KRAS G12D and ESR1 mutations, and CDK4 and CDK2 further expand the landscape of precision oncology
Evidence from tailored programmes in breast cancer show that a more holistic approach is needed to support patients to find the motivation to take up an active lifestyle
However, the future of TKI combinations for these rare tumours is uncertain
ESMO outlined several actions for Member States on three priority areas – prevention, healthcare systems, cancer workforce
New indication concerns a combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant
The Molecular Analysis for Precision Oncology Congress 2024 (MAP) is the appointment where globally recognised experts will present and discuss research in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics
During the patient session on 11 October 2024 at HDIO Congress, a Croatian-language version of the ESMO Patient Guide on Bone Health in Cancer was presented. This guide was translated by Sve za Nju in collaboration with HDIO
While the new WHO guidelines address key aspects of trial inclusivity and design, ESMO continues to push for stronger prioritization of cancer and rare diseases
Overall survival results from the second interim analysis of the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Final results from the CheckMate 067 study
Updated data from two studies report significant improvements in recurrence-free survival and distant-metastasis free survival with pembrolizumab or nivolumab
Findings from the TiNivo-2 study
New indication concerns a combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant
Overall survival results from the second interim analysis of the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Final results from the CheckMate 067 study
Findings from the TiNivo-2 study
Evidence for efficacy is based on the results from the LAURA study
New indications concern treatment of locally advanced cervical cancer in combination with chemoradiotherapy and first-line treatment of advanced or recurrent endometrial carcinoma in combination with chemotherapy
Findings from the second interim analysis of the KEYNOTE-671 study
Findings from an updated analysis of the CIRCULATE-Japan GALAXY study
Evidence is based on the results from the IMscin001 study
The Molecular Analysis for Precision Oncology Congress 2024 (MAP) is the appointment where globally recognised experts will present and discuss research in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics
Immunotherapy, which works by enabling the body’s immune system to recognise and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large international studies reported at ESMO 2024
Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found ‘promising’ antitumour activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers
The ESMO Congress 2024 taking place 13-17 September in Barcelona, Spain, offers a comprehensive view of the current drug development landscape, with existing medicines demonstrating benefit in additional applications and new agents emerging in large numbers as the range of potential molecular targets for therapy continues to expand
The ESMO Congress 2024 will hold a press conference to introduce and discuss the “Eyes to the Future” Presidential Symposium 3, that will be presenting prominent approaches that have the potential to become increasingly effective and influential components of cancer treatment in the (near) future.
The European Society for Medical Oncology (ESMO) is calling on all actors of the oncology community to commit to improving the well-being of the cancer workforce and join in 11 actions outlined in a paper published today in ESMO Open
According to two international studies presented at the ESMO Congress 2024, women who breastfeed after receiving treatment for breast cancer, including those with a germline BRCA mutation (an inherited change in BRCA genes that significantly increases the risk of developing certain cancers, especially breast cancer), do not face an increased risk of recurrence or developing new breast cancers
The ESMO Congress 2024 will take place from September 13-17 in Barcelona, bringing together participants from all over the world
Treatment of gastrointestinal (GI) cancers is catching up with other areas of oncology and offering patients better prospects for survival and quality of life, but a significant uptick in early-onset cases is raising new questions about effective prevention, diagnosis and treatment
Bringing another annual reunion of the global oncology community to a resounding close, the 34,000 attendees of the ESMO Congress 2024 had the opportunity to gather around to listen to the most important results presented in different tumour types and research areas
ESMO is pleased to announce the 2024 ESMO Fellowship awardees
The ESMO Precision Medicine Working Group (PMWG) together with a multidisciplinary team of international experts, have developed the ESMO Tumour-Agnostic Classifier and Screener (ETAC-S)
The recipients of the 2024 ESMO Society Awards have been announced today by ESMO
Hundreds of trials are being delayed in Europe due to unintended consequences of the IVDR posing an existential threat to Europe’s role as a leader in global oncological research
The Impact Factor (IF) of ESMO journals has remained strong this year, according to the 2024 Journal Citation Reports published by Clarivate Analytics
ESMO has announced today the results of its Presidential elections following the closure of the voting system on Monday, 10 June 2024.
Tom Powles, Editor in Chief of ESMO’s flagship journal Annals of Oncology; Solange Peters, ESMO Past President; and Fabrice André, President Elect of the Society have been recognised as leading and influential researchers for their remarkable achievements in cancer care
Following the Ombudsman’s recent findings of maladministration regarding the Commission’s interactions with tobacco lobbyists and its subsequent decision not to bring forward the proposed Council recommendation on smoke-free environments, it is beyond belief that the Commission now appears to have removed plans to publish an evaluation – originally meant to come in 2022 - of the Tobacco Products Directive from its implementation
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
United Kingdom
Spain
France
Republic of Singapore
Republic of Singapore
Republic of Singapore
Republic of Singapore
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Examination 2025 will be held on Saturday 18 October during the ESMO Congress 2025.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
